



SDI Review Form 1.6

Journal Name:	International Research Journal of Pure and Applied Chemistry
Manuscript Number:	2014_IRJPAC_13578
Title of the Manuscript:	Novel salts of Sunitinib an anticancer drug with improved solubility
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<u>Compulsory</u> REVISION comments	There are too much words joined along the manuscript; thus, this point requires a complete checking. All the abbreviated words need to be introduced before using, i.e. DI in the Abstract (line 13)., among others.	Corrected Corrected
<u>Minor</u> REVISION comments	It would be important to add a table with the pKa values of all the compounds investigated including the drug. With respect to Fig. 9 and other similar, it would be important to try to explain why the same compounds exhibit different retention times. The paragraph of lines 277 to 284 has been written before in almost the same words and I consider it should be written in other way to avoid repetition along the document. Lines 305 to 315: In this paragraph the effect of pH should be discussed as a help to evaluate the possibility of formation of both kind of compounds. Naturally, the respective pKa values are required. In Fig. 12b the symbol for this acid should be HA- to represent the dissociation of only one carboxyl group.	Incorporated. RT has shifted but RRT is same. Corrected. Incorporated in the article highlighted in yellow. Corrected



SDI Review Form 1.6

	Figs. S18, S22, S26: DSC thermograms are identified as Sunitinib malate corresponding to other salts.	Figs. S 18, S22 and S26 are corresponds to novel salts <i>i.e.</i> 4-Hydroxy benzoate, Nicotinate and Saccharate salts of sunitinib .
<u>Optional/General</u> comments		